Oncogene-induced cellular senescence (OIS) is emerging as a potent cancer-protective
response to oncogenic events, serving to eliminate early neoplastic cells from the …

Oncogene-induced cellular senescence (OIS) is a complex program that is triggered in
response to aberrant activation of oncogenic signaling. Initially, OIS was thought to be a …

Oncogene-induced senescence (OIS) is a powerful intrinsic tumor-suppressive mechanism,
arresting cell cycle progression upon oncogene-activating genomic alterations. The …

The senescent phenotype was first described in 1961 as a phenomenon characterized by
the cessation of cellular division. After years of debate as to whether it represented a tissue …

The well-recognized cell phenotypic heterogeneity in tumors is a great challenge for cancer
treatment. Dynamic interconversion and movement within a spectrum of different cell …

Oncogene-induced senescence (OIS) is characterized by increased expression of the cell
cycle inhibitor p16, leading to a hallmark cell cycle arrest. Suppression of p16 in this context …

Cellular senescence has emerged as a potent tumor suppressor mechanism in numerous
human neoplasias. Senescent cells secrete a distinct set of factors, collectively termed the …

Cellular senescence is a permanent growth arrest that is broadly recognized to act as a
barrier against tumorigenesis. Senescence is predominant in premalignant tumors, and …

Oncogene-induced senescence (OIS) is crucial for tumour suppression. Senescent cells
implement a complex pro-inflammatory response termed the senescence-associated …

Inflammation acts as a double-edged sword in the pathogenesis of cancer. Inflammatory
responses play a key role in eliminating potentially cancerous cells; however, an …